Quick answer : The most clinically important advantage of ketamine for postpartum depression is speed: meaningful antidepressant effects are typically detectable within hours to days, compared to four to six weeks for standard antidepressants. This speed matters in the postpartum period, where the mother-infant bonding window is time-sensitive. Spravato (esketamine), which has insurance coverage pathways, is available for qualifying patients at Seaside Ketamine’s Cardiff and Newport Beach locations. A 24-hour pump-and-discard protocol is used for breastfeeding patients as a precautionary measure.
The expectation is joy. The reality, for far too many women, looks nothing like the picture they were promised.
Postpartum depression affects roughly one in seven new mothers. That number only includes women who report their symptoms. The actual number may be higher because postpartum depression remains significantly underreported. It also carries a unique kind of shame. You are supposed to feel the most love you have ever felt. Instead, you may feel nothing, dread, or a grief you cannot explain.
I want to talk about what happens when standard treatments for PPD are not enough. I also want to explain why ketamine has become an important area of research and treatment for this population.
Doctors typically use an SSRI antidepressant as a first-line treatment for postpartum depression. Common examples include sertraline, escitalopram, and similar medications. Therapy can also play an important role when patients can access it.
For many women, these treatments work. For a meaningful minority, they do not provide enough relief. Some women experience difficult side effects. Others do not respond well enough to the medication. The four-to-six-week wait for an antidepressant to take effect can also feel far too long when symptoms severely affect daily life.
Newer FDA-approved treatments specifically target postpartum depression. These include Zulresso (brexanolone), a 60-hour IV infusion, and Zurzuvae (zuranolone), an oral medication taken for 14 days.
These treatments represent significant advances in PPD care. However, they are not universally accessible, and they do not work for every patient.
When women try one or more treatments without adequate relief, clinicians may consider treatment-resistant PPD. This is where ketamine enters the conversation.
With many forms of depression, waiting six to eight weeks for another antidepressant trial can take a major toll on quality of life. Postpartum depression creates a different set of concerns.
The first months of a child’s life represent an important period for the mother-infant bond. Severe PPD can make it harder for a mother to connect with her baby and respond to the baby’s needs. It can also cause significant emotional suffering for the mother.
Treatment that works in weeks can help more than treatment that takes months. Treatment that works within days may offer an even faster path toward relief for some patients.
One of ketamine’s most distinctive clinical properties is its potential for rapid antidepressant effects. Some patients experience meaningful improvement within hours to days rather than weeks.
For a new mother who feels like she is missing her child’s early life while waiting for another medication to work, that speed can matter. It may offer more than symptom relief. It may give her an opportunity to reconnect with her baby and daily life sooner.
Most breastfeeding mothers ask about this before anything else. They deserve a clear and honest answer.
The body metabolizes and clears ketamine relatively quickly. The half-life of ketamine and its active metabolites occurs over hours rather than days. However, researchers do not have robust clinical trial data that fully characterizes ketamine levels in breast milk or its effects on nursing infants.
Because of this limited data, our clinical approach uses a “pump and discard” protocol for 24 hours after an infusion as a precaution.
Every breastfeeding patient should discuss this decision directly with her physician and pediatrician. The right choice can differ from one mother to another.
For some mothers, continuing to breastfeed takes priority over ketamine treatment. We respect that choice, and other treatment options may be available.
For others, the severity of their PPD and the limitations of previous treatments make ketamine a priority. These mothers may choose to use formula or stored breast milk during the treatment period.
Neither decision deserves judgment. Every mother deserves honest information so she can make an informed choice with her healthcare providers.
For postpartum patients with qualifying insurance, Spravato (esketamine) may also be worth discussing.
Spravato has FDA-approved indications for certain forms of major depressive disorder and established insurance coverage pathways. For eligible patients, insurance may reduce the out-of-pocket cost compared with IV ketamine.
Spravato also has an indication for adults with major depressive disorder who experience acute suicidal ideation or behavior. Suicidal thoughts can occur with postpartum depression and require immediate clinical attention.
Seaside Ketamine is a certified Spravato treatment site at both our Cardiff and Newport Beach locations.
We take PPD evaluations seriously because postpartum patients have unique needs and the stakes can be high.
Before recommending any ketamine treatment, we conduct a thorough evaluation. This includes:
The severity and duration of symptoms
Previous treatment history
Previous use of PPD-specific treatments, when applicable
Current medications
Breastfeeding status and plans
Support available at home
Any current safety concerns
When appropriate, we also coordinate with the patient’s OB and pediatrician.
If you are a new mother who is suffering and feels like you have run out of options, you do not have to navigate this alone.
If you are a partner or parent watching someone struggle with postpartum depression, you can also reach out for information.
The consultation is free and completely confidential. You deserve to understand your options and learn what may be appropriate for your situation.
This deserves a straight answer: we don’t have robust clinical trial data specifically characterizing ketamine concentrations in breast milk or effects on nursing infants. What we know is that ketamine is metabolized and cleared relatively quickly, with active metabolites on the order of hours. Our clinical protocol is a 24-hour pump-and-discard period following each infusion as a precautionary measure. Every patient’s situation is individual, and this is a conversation to have directly with Dr. Gillin and your pediatrician — not a decision that should be made based on a blog post alone. For some mothers, the severity of PPD and the limitations of other treatments make this a clear priority decision. For others, breastfeeding takes precedence and we explore alternatives accordingly.
Zulresso (brexanolone) and Zurzuvae (zuranolone) are specifically FDA-approved for PPD — they work through the neurosteroid system and were developed specifically with postpartum neurobiological changes in mind. For women who meet criteria and can access them, they’re genuinely worth considering first. Ketamine is not FDA-approved specifically for PPD — it’s used for PPD that hasn’t responded to other treatments, or when rapid effect is urgently needed and the approved options aren’t accessible or haven’t worked. We’ll have an honest conversation about where ketamine fits in your specific treatment sequence during the intake evaluation.
Six weeks on an antidepressant without adequate relief in the context of significant PPD is a reasonable point to reassess the approach — you don’t need to wait indefinitely. At that point, you meet the early definition of treatment-resistant PPD and the evidence base for ketamine becomes relevant. The first step is a free consultation with us, ideally with a summary of what you’ve tried and how you responded. We may also recommend looping in a maternal mental health specialist if you’re not already connected with one — this is a population that benefits from coordinated care, and we function well as part of a team rather than a standalone intervention.
